GlaxoSmithKline announces board changes early
pharmafile | February 26, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | GSK, GlaxoSmithKline, Tom de Swaan, christopher gent, sir philip hampton
GlaxoSmithKline has confirmed that Sir Christopher Gent will step down early as chairman of GSK in May to be succeeded by The Royal Bank of Scotland’s Sir Philip Hampton.
Sir Philip (pictured) who joined GSK as an independent non-executive director at the beginning of the year was due to take over from September, but now will become deputy chairman from April. He chairs the company’s nominations committee and will remain chairman of RBS until 31 August.
In addition, Tom de Swaan who is an independent non-executive director, is not seeking re-election to GSK’s board. He has been a member for nine years and is currently chairman of various committees at the company. Jing Ulrich has also decided not to stand again as a member.
Not averse to joining large firms during a period of trouble, Sir Philip took over as RBS chairman in 2009 following the bank’s bailout during the financial crisis.
Sir Philip had to not only steer RBS through choppy financial waters there, but also deal with the fallout of its previous chief executive Fred Goodwin (also known via the moniker ‘Fred the shred’ after making large cuts in the firm) who stepped down in early 2009, just as it was announced that the firm had lost £24 billion in 2008 under his watch.
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …
